CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
LipUm is developing a novel therapeutic antibody targeting Bile Salt-Stimulated Lipase to treat rheumatoid arthritis and other inflammatory diseases. This approach aims to inhibit inflammation and prevent joint damage, addressing a significant medical need.
LipUm has discovered a novel treatment of rheumatoid arthritis (RA) and potentially other inflammatory diseases by a uniquetherapeutic antibody directed towards the Bile Salt-Stimulated Lipase, which has been identified as a key target to block andthereby inhibit the inflammatory process and prevent joint destruction.The global prevalence of RA is 0.3-1%, and it is twice as common among woman than men, and the risk to develop thecondition increases by age.
Frequently, other serious diseases are…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
